$PULM
Pulmatrix Inc

2023 Q1 Form 10-K Financial Statement

#000149315223009609 Filed on March 30, 2023

View on sec.gov

Income Statement

Concept 2023 Q1 2022 Q4 2022
Revenue $1.499M $1.708M $6.071M
YoY Change 29.22% 274.56% 17.45%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.210M $1.566M $6.778M
YoY Change 11.96% 1.69% 6.29%
% of Gross Profit
Research & Development $3.874M $4.467M $18.24M
YoY Change -6.63% 50.96% 18.58%
% of Gross Profit
Depreciation & Amortization $32.00K $39.00K $162.0K
YoY Change -8.57% 11.43% -4.14%
% of Gross Profit
Operating Expenses $6.084M $6.033M $25.02M
YoY Change -0.64% 34.1% 14.98%
Operating Profit -$4.585M -$18.95M
YoY Change -7.62% -6.05%
Interest Expense $222.0K $191.0K $309.0K
YoY Change 22100.0% 19000.0% 4314.29%
% of Operating Profit
Other Income/Expense, Net $137.0K -$82.00K $111.0K
YoY Change -1345.45% -845.45% -1109.09%
Pretax Income -$4.448M -$4.216M -$18.84M
YoY Change -10.56% 4.59% -6.62%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$4.448M -$4.216M -$18.84M
YoY Change -10.56% 4.59% -6.62%
Net Earnings / Revenue -296.73% -246.84% -310.26%
Basic Earnings Per Share -$1.22 -$5.46
Diluted Earnings Per Share -$1.22 -$1.16 -$5.46
COMMON SHARES
Basic Shares Outstanding 3.652M shares 3.639M shares 3.448M shares
Diluted Shares Outstanding 3.651M shares 3.448B shares

Balance Sheet

Concept 2023 Q1 2022 Q4 2022
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.75M $35.63M $35.63M
YoY Change -35.3% -33.83% -33.83%
Cash & Equivalents $30.75M $35.63M $35.63M
Short-Term Investments
Other Short-Term Assets $1.307M $1.221M $1.221M
YoY Change -33.35% 40.18% 40.18%
Inventory
Prepaid Expenses
Receivables $740.0K $1.298M $1.298M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $32.80M $38.15M $38.15M
YoY Change -35.19% -30.36% -30.36%
LONG-TERM ASSETS
Property, Plant & Equipment $203.0K $235.0K $945.0K
YoY Change -90.19% -90.27% -60.85%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $899.0K $389.0K $1.861M
YoY Change -44.68% -76.06% 14.52%
Total Long-Term Assets $3.259M $2.806M $2.806M
YoY Change -11.8% -30.53% -30.53%
TOTAL ASSETS
Total Short-Term Assets $32.80M $38.15M $38.15M
Total Long-Term Assets $3.259M $2.806M $2.806M
Total Assets $36.06M $40.95M $40.95M
YoY Change -33.6% -30.37% -30.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $578.0K $1.188M $1.188M
YoY Change -52.89% 41.6% 41.6%
Accrued Expenses $2.441M $2.495M $2.495M
YoY Change -7.29% -6.34% -6.34%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.732M $5.022M $5.022M
YoY Change -12.0% 13.06% 13.06%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.317M $4.822M $4.822M
YoY Change -30.02% -30.38% -30.38%
Total Long-Term Liabilities $4.317M $4.822M $4.822M
YoY Change -30.02% -30.38% -30.38%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.732M $5.022M $5.022M
Total Long-Term Liabilities $4.317M $4.822M $4.822M
Total Liabilities $9.049M $9.844M $9.844M
YoY Change -21.63% -13.41% -13.41%
SHAREHOLDERS EQUITY
Retained Earnings -$277.9M -$273.5M
YoY Change 7.4%
Common Stock $0.00 $0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $27.01M $31.11M $31.11M
YoY Change
Total Liabilities & Shareholders Equity $36.06M $40.95M $40.95M
YoY Change -33.6% -30.37% -30.37%

Cashflow Statement

Concept 2023 Q1 2022 Q4 2022
OPERATING ACTIVITIES
Net Income -$4.448M -$4.216M -$18.84M
YoY Change -10.56% 4.59% -6.62%
Depreciation, Depletion And Amortization $32.00K $39.00K $162.0K
YoY Change -8.57% 11.43% -4.14%
Cash From Operating Activities -$4.928M -$5.046M -$19.36M
YoY Change -19.79% 14.79% -1.88%
INVESTING ACTIVITIES
Capital Expenditures $9.000K $86.00K
YoY Change -134.62% -159.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$9.000K -$86.00K
YoY Change -65.38% -40.28%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.382M
YoY Change -96.82%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $53.00K 0.000 $1.230M
YoY Change -134.87% -100.0% -97.17%
NET CHANGE
Cash From Operating Activities -$4.928M -5.046M -$19.36M
Cash From Investing Activities -9.000K -$86.00K
Cash From Financing Activities $53.00K 0.000 $1.230M
Net Change In Cash -$4.875M -5.055M -$18.21M
YoY Change -22.69% -385.59% -177.16%
FREE CASH FLOW
Cash From Operating Activities -$4.928M -$5.046M -$19.36M
Capital Expenditures $9.000K $86.00K
Free Cash Flow -$4.928M -$5.055M -$19.44M
YoY Change -19.66% 15.68% -0.72%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022 PULM Beneficial Conversion Feature Of Preferred Stock
BeneficialConversionFeatureOfPreferredStock
usd
CY2022 PULM Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
usd
CY2021Q4 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
usd
CY2022Q4 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
usd
CY2022 dei Entity Central Index Key
EntityCentralIndexKey
0001574235
CY2022 dei Amendment Flag
AmendmentFlag
false
CY2022 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
usd
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
usd
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
CY2022 PULM Deemed Dividend Beneficial Conversion Feature Of Preferred Stock
DeemedDividendBeneficialConversionFeatureOfPreferredStock
usd
CY2021 PULM Stock Issued During Period Value Conversion Of Convertible Securities One
StockIssuedDuringPeriodValueConversionOfConvertibleSecuritiesOne
usd
CY2021 PULM Deemed Dividend Related To Benecial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBenecialConversionFeatureOfPreferredStock
usd
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
usd
CY2022 PULM Stock Issued During Period Value Adjustment Due To Reverse Stock Split
StockIssuedDuringPeriodValueAdjustmentDueToReverseStockSplit
usd
CY2022 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
usd
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
usd
CY2022 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
usd
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
usd
CY2022 PULM Fixed Asset Purchases In Accounts Payable
FixedAssetPurchasesInAccountsPayable
usd
CY2022 PULM Issuance Costs In Accounts Payable
IssuanceCostsInAccountsPayable
usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2022 PULM Preferred Stock Issuance Costs Associated With Placement Agent Warrants
PreferredStockIssuanceCostsAssociatedWithPlacementAgentWarrants
usd
CY2022 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
usd
CY2022 PULM Effective Income Tax Rate Reconciliation Writedown Of Godwill Percent
EffectiveIncomeTaxRateReconciliationWritedownOfGodwillPercent
pure
CY2022 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2021 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
pure
CY2021Q4 PULM Deferred Tax Assets Deferred Expense Capitalized Research And Development
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment
usd
CY2022Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2021Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
usd
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
usd
CY2022 dei Document Type
DocumentType
10-K
CY2022 dei Document Annual Report
DocumentAnnualReport
true
CY2022 dei Document Period End Date
DocumentPeriodEndDate
2022-12-31
CY2022 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022 dei Document Transition Report
DocumentTransitionReport
false
CY2022 dei Entity File Number
EntityFileNumber
001-36199
CY2022 dei Entity Registrant Name
EntityRegistrantName
PULMATRIX, INC.
CY2022 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-1821392
CY2022 dei Entity Address Address Line1
EntityAddressAddressLine1
99 Hayden Avenue
CY2022 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 390
CY2022 dei Entity Address City Or Town
EntityAddressCityOrTown
Lexington
CY2022 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02421
CY2022 dei City Area Code
CityAreaCode
781
CY2022 dei Local Phone Number
LocalPhoneNumber
357-2333
CY2022 dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
CY2022 dei Trading Symbol
TradingSymbol
PULM
CY2022 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2022 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2022 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022 dei Entity Small Business
EntitySmallBusiness
true
CY2022 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2022 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
true
CY2022 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Public Float
EntityPublicFloat
15546729 usd
CY2023Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
3652285 shares
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Firm
AuditorFirmId
688
CY2022 dei Auditor Name
AuditorName
Marcum LLP
CY2022 dei Auditor Location
AuditorLocation
New York, NY
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35628000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53840000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
153000 usd
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1298000 usd
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
67000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1068000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
871000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
38147000 usd
CY2021Q4 us-gaap Assets Current
AssetsCurrent
54778000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000 usd
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
710000 usd
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2093000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1625000 usd
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
389000 usd
CY2022Q4 us-gaap Assets
Assets
40953000 usd
CY2021Q4 us-gaap Assets
Assets
58817000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1188000 usd
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
839000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1638000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1233000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
857000 usd
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1431000 usd
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1339000 usd
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
939000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5022000 usd
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4442000 usd
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4822000 usd
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6069000 usd
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
857000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
9844000 usd
CY2021Q4 us-gaap Liabilities
Liabilities
11368000 usd
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
1081000 usd
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3639185 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3639185 shares
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3222037 shares
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3222037 shares
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
304585000 usd
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
301008000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-273476000 usd
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-254640000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31109000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
40953000 usd
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58817000 usd
CY2022 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
6071000 usd
CY2021 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5169000 usd
CY2022 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
18240000 usd
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
15382000 usd
CY2022 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6778000 usd
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6377000 usd
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
CY2022 us-gaap Operating Expenses
OperatingExpenses
25018000 usd
CY2021 us-gaap Operating Expenses
OperatingExpenses
25336000 usd
CY2022 us-gaap Operating Income Loss
OperatingIncomeLoss
-18947000 usd
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-20167000 usd
CY2022 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
309000 usd
CY2021 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
7000 usd
CY2022 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-198000 usd
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-11000 usd
CY2022 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
111000 usd
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18836000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20171000 usd
CY2021 PULM Deemed Dividend Beneficial Conversion Feature Of Preferred Stock
DeemedDividendBeneficialConversionFeatureOfPreferredStock
-3197000 usd
CY2022 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-18836000 usd
CY2021 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23368000 usd
CY2022 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-5.46
CY2021 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.63
CY2022 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3447701 shares
CY2021 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2708558 shares
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
23139000 usd
CY2021 PULM Stock Issued During Period Value New Issues Warrant
StockIssuedDuringPeriodValueNewIssuesWarrant
6040000 usd
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
37079000 usd
CY2021 PULM Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
204000 usd
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1158000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20171000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
47449000 usd
CY2022 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1382000 usd
CY2022 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1114000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18836000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31109000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
31109000 usd
CY2022 us-gaap Net Income Loss
NetIncomeLoss
-18836000 usd
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-20171000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
162000 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169000 usd
CY2022 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1383000 usd
CY2021 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1067000 usd
CY2022 us-gaap Share Based Compensation
ShareBasedCompensation
1114000 usd
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
1158000 usd
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
CY2022 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1231000 usd
CY2021 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-17000 usd
CY2022 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
197000 usd
CY2021 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
148000 usd
CY2022 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
389000 usd
CY2022 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
511000 usd
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-149000 usd
CY2022 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
405000 usd
CY2021 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-795000 usd
CY2022 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1431000 usd
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1126000 usd
CY2022 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-847000 usd
CY2021 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-3326000 usd
CY2022 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19356000 usd
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19727000 usd
CY2022 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
86000 usd
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
144000 usd
CY2022 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-86000 usd
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-144000 usd
CY2022 PULM Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
-152000 usd
CY2021 PULM Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts
6192000 usd
CY2022 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1382000 usd
CY2021 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
37079000 usd
CY2021 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
204000 usd
CY2022 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1230000 usd
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
43475000 usd
CY2022 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-18212000 usd
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
23604000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55465000 usd
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
31861000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37253000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55465000 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35628000 usd
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
53840000 usd
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
153000 usd
CY2022Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1472000 usd
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
1625000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37253000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55465000 usd
CY2022 PULM Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
1081000 usd
CY2021 PULM Conversion Of Preferred Stock To Common Stock
ConversionOfPreferredStockToCommonStock
2903000 usd
CY2021 PULM Fixed Asset Purchases In Accounts Payable
FixedAssetPurchasesInAccountsPayable
10000 usd
CY2021 PULM Issuance Costs In Accounts Payable
IssuanceCostsInAccountsPayable
152000 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1671000 usd
CY2021 PULM Preferred Stock Issuance Costs Associated With Placement Agent Warrants
PreferredStockIssuanceCostsAssociatedWithPlacementAgentWarrants
300000 usd
CY2021 PULM Beneficial Conversion Feature Of Preferred Stock
BeneficialConversionFeatureOfPreferredStock
3197000 usd
CY2021 PULM Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
3197000 usd
CY2022Q1 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
CY2022Q4 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
51000 usd
CY2021Q4 us-gaap Deposits Money Market Deposits
DepositsMoneyMarketDeposits
51000 usd
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
500000 shares
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Area Of Land
AreaOfLand
22000
CY2022 us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84D_eus-gaap--UseOfEstimates_zWmcT6Iz05Dg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_z44w7jiyI3A1">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In preparing consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results may differ from these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. The most significant estimates and assumptions in the Company’s consolidated financial statements include, but are not limited to, estimates of future expected costs in order to derive and recognize revenue, estimates related to clinical trial accruals and upfront deposits, fair value used to record preferred stock and warrants transactions, incremental borrowing rate, and accounting for income taxes and the related valuation allowance.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zLJtHBstgp9e" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span id="xdx_86C_zzyJwAvVKqoc" style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Concentrations of Credit Risk</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash is a financial instrument that potentially subjects the Company to concentrations of credit risk. For all periods presented, substantially all of the Company’s cash was deposited in accounts at a single financial institution that management believes is creditworthy. The Company is exposed to credit risk in the event of default by these financial institutions for amounts in excess of the Federal Deposit Insurance Corporation insured limits. The Company maintains its cash at a high-quality financial institution and has not incurred any losses to date.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For the year ended December 31, 2022, revenue from one customer accounted for approximately <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zEN4qV46VFej" title="Concentration risk percentage">99%</span> of revenue recognized in the consolidated statements of operations. For the year ended December 31, 2021, revenue from two customers accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--RevenueFromContractWithCustomerMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--TwoCustomersMember_zsp3GLFV9YKj" title="Concentration risk percentage">99%</span> of revenue recognized in the consolidated statements of operations. As of December 31, 2022 and 2021, one customer accounted for <span id="xdx_901_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zWPwFi3Fcbw6" title="Concentration risk percentage">100%</span> and <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20210101__20211231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--OneCustomerMember_zA4Ft9Kz7Z0i" title="Concentration risk percentage">96%</span> of accounts receivable, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2022Q4 us-gaap Other Commitment
OtherCommitment
5200000 usd
CY2022Q4 us-gaap Other Commitment Due In Next Twelve Months
OtherCommitmentDueInNextTwelveMonths
4200000 usd
CY2021 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
3577000 usd
CY2022Q4 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
517000 usd
CY2021Q4 PULM Prepaid Clinical And Consulting
PrepaidClinicalAndConsulting
230000 usd
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
286000 usd
CY2021Q4 us-gaap Prepaid Insurance
PrepaidInsurance
325000 usd
CY2022Q4 PULM Prepaid Software And Hosting Costs
PrepaidSoftwareAndHostingCosts
99000 usd
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
166000 usd
CY2021Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
316000 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1068000 usd
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
871000 usd
CY2022 PULM Agreement Description
AgreementDescription
The Company and Cipla will each be responsible for 60% and 40%, respectively, of the Company’s overhead costs and the time spent by the Company’s employees and consultants on development of the Product (“Direct Costs”), in addition to which, Cipla will reimburse the Company an amount equal to 10% of aggregate Direct Costs upon the achievement of the development milestones set forth in the table below, potentially bringing the sharing of Direct Costs to a 50/50 basis. The Company will continue to share all other development costs with Cipla that are not Direct Costs, such as the cost of clinical research organizations, manufacturing costs and other third-party costs, on a 50/50 basis
CY2022Q4 PULM Transaction Costs
TransactionCosts
22000000.0 usd
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2983000 usd
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2961000 usd
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2748000 usd
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2640000 usd
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
235000 usd
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
321000 usd
CY2022 us-gaap Depreciation And Amortization
DepreciationAndAmortization
162000 usd
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
169000 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1130000 usd
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1051000 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
475000 usd
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
97000 usd
CY2021Q4 PULM Accrued Legal And Patent Current
AccruedLegalAndPatentCurrent
58000 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33000 usd
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
27000 usd
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1638000 usd
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
1233000 usd
CY2021Q4 us-gaap Preferred Stock Voting Rights
PreferredStockVotingRights
The Series A Preferred Stock does not have any mandatory redemption provisions, contingently redeemable redemption provisions, preferential dividend rights, liquidation preferences, or voting rights, apart from mirrored, non-discretionary voting rights with common stock as a single class, equal to 100,000 votes per share of common stock underlying the Series A Preferred Stock on the Reverse Stock Split proposal which was approved by the Company’s stockholders at a special stockholder meeting on February 10, 2022
CY2021Q4 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P5Y
CY2021 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
7202 shares
CY2021 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
200000 usd
CY2021 PULM Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerm
P3Y3M18D
CY2022 PULM Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerm
P2Y11M23D
CY2022 PULM Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Non Options Outstanding Weighted Average Remaining Contractual Terms
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsNonOptionsOutstandingWeightedAverageRemainingContractualTerms
P2Y6M10D
CY2022 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1114000 usd
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1158000 usd
CY2022 us-gaap Payments To Acquire In Process Research And Development
PaymentsToAcquireInProcessResearchAndDevelopment
5200000 usd
CY2022 us-gaap Reimbursement From Limited Partnership Investment
ReimbursementFromLimitedPartnershipInvestment
2500000 usd
CY2022 us-gaap Operating Lease Cost
OperatingLeaseCost
1430000 usd
CY2021 us-gaap Operating Lease Cost
OperatingLeaseCost
1135000 usd
CY2022 us-gaap Variable Lease Cost
VariableLeaseCost
695000 usd
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
417000 usd
CY2022 us-gaap Lease Cost
LeaseCost
2125000 usd
CY2021 us-gaap Lease Cost
LeaseCost
1552000 usd
CY2022 us-gaap Operating Lease Payments
OperatingLeasePayments
1478000 usd
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
1194000 usd
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1671000 usd
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P0Y6M
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0297 pure
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0297 pure
CY2022Q4 PULM Lessee Operating Lease Liability Payments Due Next Half Year
LesseeOperatingLeaseLiabilityPaymentsDueNextHalfYear
862000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
862000 usd
CY2022Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
857000 usd
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
857000 usd
CY2022Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
857000 usd
CY2022 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.060 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.050 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.049 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Research
EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
0.018 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.025 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.003 pure
CY2021 PULM Effective Income Tax Rate Reconciliation Writedown Of Godwill Percent
EffectiveIncomeTaxRateReconciliationWritedownOfGodwillPercent
0.037 pure
CY2022 PULM Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
-0.009 pure
CY2021 PULM Effective Income Tax Rate Reconciliation Nondeductible Expense Permanent Differences
EffectiveIncomeTaxRateReconciliationNondeductibleExpensePermanentDifferences
0.003 pure
CY2022 PULM Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses
EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses
0.008 pure
CY2021 PULM Effective Income Tax Reconciliation Limitations On Credit And Net Operating Losses
EffectiveIncomeTaxReconciliationLimitationsOnCreditAndNetOperatingLosses
0.163 pure
CY2022 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.295 pure
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
0.072 pure
CY2022Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
11557000 usd
CY2021Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
10836000 usd
CY2022Q4 PULM Deferred Tax Assets Deferred Expense Capitalized Research And Development
DeferredTaxAssetsDeferredExpenseCapitalizedResearchAndDevelopment
4460000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
698000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
12000 usd
CY2022Q4 PULM Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
293000 usd
CY2021Q4 PULM Deferred Tax Assets Deferred Expense Capitalized Startup
DeferredTaxAssetsDeferredExpenseCapitalizedStartup
432000 usd
CY2022Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
860000 usd
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
815000 usd
CY2022Q4 PULM Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
234000 usd
CY2021Q4 PULM Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
625000 usd
CY2022Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2206000 usd
CY2021Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
2415000 usd
CY2022Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
20308000 usd
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
15135000 usd
CY2022Q4 PULM Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
194000 usd
CY2021Q4 PULM Deferred Tax Liability Right Of Use Asset
DeferredTaxLiabilityRightOfUseAsset
572000 usd
CY2022Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
194000 usd
CY2021Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
572000 usd
CY2022Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
20114000 usd
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
14563000 usd
CY2022 us-gaap Operating Loss Carryforwards Limitations On Use
OperatingLossCarryforwardsLimitationsOnUse
federal net operating loss carryforwards of approximately $53.2 million available to reduce future taxable income, of which $3.8 million is subject to expiration between 2026 and 2037 and $49.4 million may be carried forward indefinitely
CY2022Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
53200000 usd
CY2022 PULM Operating Loss Carryforwards Expiration Date Description
OperatingLossCarryforwardsExpirationDateDescription
expiration between 2030 and 2042
CY2022 PULM Deferred Tax Assets Tax Credit Carryforwards Expiration Date Description
DeferredTaxAssetsTaxCreditCarryforwardsExpirationDateDescription
expiration at various times through 2042
CY2022Q4 PULM Percentage Of Net Operating Losses Utilization
PercentageOfNetOperatingLossesUtilization
0.50 pure
CY2022 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
5600000 usd
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0 usd
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
130000 usd
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
130000 usd
CY2022 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
229000 usd
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
229000 usd
CY2022 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1589626 shares
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1888249 shares

Files In Submission

Name View Source Status
0001493152-23-009609-index-headers.html Edgar Link pending
0001493152-23-009609-index.html Edgar Link pending
0001493152-23-009609.txt Edgar Link pending
0001493152-23-009609-xbrl.zip Edgar Link pending
ex23-1.htm Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-k.htm Edgar Link pending
MetaLinks.json Edgar Link pending
pulm-20221231.xsd Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
pulm-20221231_def.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
pulm-20221231_pre.xml Edgar Link unprocessable
form10-k_htm.xml Edgar Link completed
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
pulm-20221231_cal.xml Edgar Link unprocessable
pulm-20221231_lab.xml Edgar Link unprocessable